GT Biopharma, Inc. (GTBP)
After hours:
| Previous Close | 2.9000 |
| Open | 2.8700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.8700 - 3.1500 |
| 52 Week Range | 1.9200 - 10.6600 |
| Volume | |
| Avg. Volume | 15,067 |
| Market Cap | 6.926M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.7600 |
| Earnings Date | Nov 08, 2024 - Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireGT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma’s Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies fo
- GlobeNewswire
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here. The event will feature Jeffrey Miller, MD1 and Mark Juckett, MD from the University of Minnesot
